These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11435891)
1. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells. Chang FL; Lai MD J Urol; 2001 Jul; 166(1):304-10. PubMed ID: 11435891 [TBL] [Abstract][Full Text] [Related]
2. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. Chang FL; Ling YF; Lai MD Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676 [TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Sato S; Kigawa J; Minagawa Y; Okada M; Shimada M; Takahashi M; Kamazawa S; Terakawa N Cancer; 1999 Oct; 86(7):1307-13. PubMed ID: 10506718 [TBL] [Abstract][Full Text] [Related]
4. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Chang FL; Lai MD Anticancer Res; 2000; 20(1A):351-5. PubMed ID: 10769679 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Miyake H; Hara I; Gohji K; Yamanaka K; Arakawa S; Kamidono S Anticancer Res; 1998; 18(4C):3087-92. PubMed ID: 9713515 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342 [TBL] [Abstract][Full Text] [Related]
7. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Li R; Sutphin PD; Schwartz D; Matas D; Almog N; Wolkowicz R; Goldfinger N; Pei H; Prokocimer M; Rotter V Oncogene; 1998 Jun; 16(25):3269-77. PubMed ID: 9681825 [TBL] [Abstract][Full Text] [Related]
9. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Puca R; Nardinocchi L; Pistritto G; D'Orazi G Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylated and hypoacetylated mutant p53 enhances cisplatin-induced apoptosis through caspase-9 pathway in the absence of transcriptional activation or translation. Lai MD; Lin WC; Sun YM; Chang FL Int J Mol Med; 2005 Apr; 15(4):725-34. PubMed ID: 15754039 [TBL] [Abstract][Full Text] [Related]
12. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915 [TBL] [Abstract][Full Text] [Related]
13. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Chan KT; Lung ML Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724 [TBL] [Abstract][Full Text] [Related]
14. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point. Wang LH; Okaichi K; Ihara M; Okumura Y Anticancer Res; 1998; 18(1A):321-5. PubMed ID: 9568097 [TBL] [Abstract][Full Text] [Related]
16. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206 [TBL] [Abstract][Full Text] [Related]
17. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810 [TBL] [Abstract][Full Text] [Related]
18. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963 [TBL] [Abstract][Full Text] [Related]
19. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Hao J; Song X; Song B; Liu Y; Wei L; Wang X; Yu J Cancer Gene Ther; 2008 Jul; 15(7):449-55. PubMed ID: 18421307 [TBL] [Abstract][Full Text] [Related]
20. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis. Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]